ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BeiGene's Zanubrutinib to Be Approved in China
May 26, 2020Zanubrutinib is one of the world's best-selling BTK inhibitor, with sales in 2019 reached 8.08 billion USD. -
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
November 22, 2022InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL). -
BeiGene Receives FDA Breakthrough Therapy Designation for Zanubrutinib
January 16, 2019BeiGene announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its investigational Bruton’s tyrosine kinase (BTK) inhibitor....
Pharma Sources Insight January 2025
